Shanghai Zhabei District Central Hospital, Shanghai, China.
Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):51-5. doi: 10.3816/CLML.2010.n.005.
The purpose of this study was to evaluate the efficacy and tolerability of continuous low-dose cyclophosphamide and prednisone (CP) as a salvage therapy for multiple myeloma (MM).
A total of 27 consecutive patients with MM received a treatment regimen that consisted of oral cyclophosphamide 50 mg and prednisone 15 mg daily. Nineteen patients had severe comorbid conditions; 8 were unwilling to continue conventional chemotherapy as a result of severe infection associated with the conventional chemotherapy. Patients had received 1 to 4 chemotherapeutic regimens before the enrollment.
The overall response rate (complete remission, very good partial response, and partial response) was 66.7%. The median time to response was 2 months. In the patients who responded to the treatment, the median progression-free survival (PFS) has not been reached. In the nonresponding patients, the median PFS was 4 months.
Continuous low-dose CP is an effective and well-tolerated salvage therapy for MM.
本研究旨在评估连续低剂量环磷酰胺和泼尼松(CP)作为多发性骨髓瘤(MM)挽救治疗的疗效和耐受性。
共 27 例 MM 患者接受了口服环磷酰胺 50mg 和泼尼松 15mg 每日的治疗方案。19 例患者合并严重并发症;8 例患者由于与常规化疗相关的严重感染而不愿意继续常规化疗。患者在入组前接受了 1 至 4 种化疗方案。
总缓解率(完全缓解、非常好的部分缓解和部分缓解)为 66.7%。缓解的中位时间为 2 个月。在对治疗有反应的患者中,中位无进展生存期(PFS)尚未达到。在无反应的患者中,中位 PFS 为 4 个月。
连续低剂量 CP 是一种有效且耐受良好的 MM 挽救治疗方法。